Nuclear Receptors and Transcription Factors in the Development of Fatty Liver Disease

E-ISSN： 1875-5453|13|10|1422-1435

ISSN： 1389-2002

Source： Current Drug Metabolism, Vol.13, Iss.10, 2012-12, pp. : 1422-1435

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Development of pro-angiogenic engineered transcription factors for the treatment of cardiovascular disease

By Rebar Edward J

Expert Opinion on Investigational Drugs, Vol. 13, Iss. 7, 2004-07 ,pp. : 829-839

Informa Healthcare

Access to resources Recommend Favorite

Xenobiotic-Sensing Nuclear Receptors CAR and PXR as Drug Targets in Cholestatic Liver Disease

Current Drug Targets, Vol. 10, Iss. 11, 2009-11 ,pp. : 1156-1163

Bentham Science Publishers

Access to resources Recommend Favorite

Nonalcoholic fatty liver disease: a review

By Poordad F Fred

Expert Opinion on Emerging Drugs, Vol. 10, Iss. 3, 2005-08 ,pp. : 661-670

Informa Healthcare

Access to resources Recommend Favorite

Innate Immune Receptors and IRF Family Transcription Factors

Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents, Vol. 4, Iss. 1, 2005-02 ,pp. : 29-33

Bentham Science Publishers

Access to resources Recommend Favorite

Nonalcoholic Fatty Liver Disease and Cardiovascular Disease

Current Pharmaceutical Design, Vol. 20, Iss. 14, 2014-04 ,pp. : 2403-2411

Bentham Science Publishers

Access to resources Recommend Favorite